Comments
Cipla has partnered with Eli Lilly to market and distribute Lilly’s insulin glargine injection, Basaglar, in India.
Eli Lilly and Company (India) Pvt Ltd is a 100 per cent subsidiary of the US-based firm. However, both the companies did not disclose the financial details of the deal. Cipla expects to start commercialising Basaglar in India by the year-end.
Cipla MD & Global CEO Umang Vohra said: “Diabetes continues to be a focus area for Cipla and with the launch of a strong brand like Basaglar, Cipla will be at the forefront of providing a holistic diabetes care with the most comprehensive portfolio across orals and injectables.”
The company’s focus continues to revolve around care continuum approach for the patients it serves and create greater access to high quality treatment and medication, he added.
Lilly India MD Luca Visini said: “This strategic partnership leverages Lilly’s commitment to bring innovation to people suffering from diabetes in India and Cipla’s strong on-ground footprint across the country.”
Cipla stock was trading up by 2.22 per cent at Rs 552.25 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.